5,734 results on '"primaquine"'
Search Results
2. An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older
- Published
- 2024
3. Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine (EFFORT)
- Author
-
University of Melbourne, National Centre for Parasitology, Entomology and Malaria Control, Cambodia, Mahidol Oxford Tropical Medicine Research Unit, Ethiopian Public Health Institute, Universitas Sumatera Utara, Arba Minch University, and Aga Khan University
- Published
- 2024
4. The effect of single low-dose primaquine treatment for uncomplicated Plasmodium falciparum malaria on haemoglobin levels in Ethiopia: a longitudinal cohort study.
- Author
-
Habtamu, Kassahun, Getachew, Hallelujah, Abossie, Ashenafi, Demissew, Assalif, Tsegaye, Arega, Degefa, Teshome, Wang, Xiaoming, Lee, Ming-Chieh, Zhou, Guofa, Kibret, Solomon, King, Christopher, Kazura, James, Petros, Beyene, Yewhalaw, Delenasaw, and Yan, Guiyun
- Subjects
Artemisinin-based combination therapies ,Ethiopia ,G6PD deficiency ,Haemoglobin ,Malaria elimination ,Plasmodium falciparum ,Primaquine ,Malaria ,Falciparum ,Humans ,Ethiopia ,Male ,Primaquine ,Adult ,Antimalarials ,Female ,Longitudinal Studies ,Hemoglobins ,Adolescent ,Young Adult ,Glucosephosphate Dehydrogenase Deficiency ,Middle Aged ,Child ,Artemisinins ,Cohort Studies ,Child ,Preschool ,Plasmodium falciparum - Abstract
BACKGROUND: To interrupt residual malaria transmission and achieve successful elimination of Plasmodium falciparum in low-transmission settings, the World Health Organization (WHO) recommends the administration of a single dose of 0.25 mg/kg (or 15 mg/kg for adults) primaquine (PQ) combined with artemisinin-based combination therapy (ACT), without glucose-6-phosphate dehydrogenase (G6PD) testing. However, due to the risk of haemolysis in patients with G6PD deficiency (G6PDd), PQ use is uncommon. Thus, this study aimed to assess the safety of a single low dose of PQ administered to patients with G6PD deficiency. METHODS: An observational cohort study was conducted with patients treated for uncomplicated P. falciparum malaria with either single-dose PQ (0.25 mg/kg) (SLD PQ) + ACT or ACT alone. Microscopy-confirmed uncomplicated P. falciparum malaria patients visiting public health facilities in Arjo Didessa, Southwest Ethiopia, were enrolled in the study from September 2019 to November 2022. Patients with uncomplicated P. falciparum malaria were followed up for 28 days through clinical and laboratory diagnosis, such as measurements of G6PD levels and haemoglobin (Hb) concentrations. G6PD levels were measured by a quantiative CareSTART™ POCT S1 biosensor machine. Patient interviews were also conducted, and the type and frequency of clinical complaints were recorded. Hb data were taken on days (D) 7, 14, 21, and 28 following treatment with SLD-PQ + ACT or ACT alone. RESULTS: A total of 249 patients with uncomplicated P. falciparum malaria were enrolled in this study. Of these, 83 (33.3%) patients received ACT alone, and 166 (66.7%) received ACT combined with SLD-PQ treatment. The median age of the patients was 20 (IQR 28-15) years. G6PD deficiency was found in 17 (6.8%) patients, 14 males and 3 females. There were 6 (7.2%) and 11 (6.6%) phenotypic G6PD-deficient patients in the ACT alone and ACT + SLD-PQ arms, respectively. The mean Hb levels in patients treated with ACT + SLD-PQ were reduced by an average of 0.45 g/dl (95% CI = 0.39 to 0.52) in the posttreatment phase (D7) compared to a reduction of 0.30 g/dl (95% CI = 0.14 to - 0.47) in patients treated with ACT alone (P = 0.157). A greater mean Hb reduction was observed on day 7 in the G6PDd ACT + SLD-PQ group (- 0.60 g/dL) than in the G6PDd ACT alone group (- 0.48 g/dL); however, there was no statistically significant difference (P = 0.465). Overall, D14 losses were 0.10 g/dl (95% CI = - 0.00 to 0.20) and 0.05 g/dl (95% CI = - 0.123 to 0.22) in patients with and without SLD-PQ, respectively (P = 0.412). CONCLUSIONS: This studys findings indicate that using SLD-PQ in combination with ACT is safe for uncomplicated P. falciparum malaria regardless of the patients G6PD status in Ethiopian settings. Caution should be taken in extrapolating this finding in other settings with diverse G6DP phenotypes.
- Published
- 2024
5. Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali (NECTAR4)
- Published
- 2024
6. Postpartum Primaquine in Breast Milk (PBC)
- Author
-
Mahidol Oxford Tropical Medicine Research Unit
- Published
- 2024
7. A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria (TADORE)
- Author
-
University of Melbourne, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Arba Minch University, Addis Ababa University, Papuan Community Health and Development Foundation, Indonesia, Eijkman Research Center for Molecular Biology, National Research and Innovation Agency, Indonesia, Curtin University, and Papua New Guinea Institute of Medical Research
- Published
- 2024
8. Short Course Radical Cure of P. Vivax Malaria in Nepal
- Author
-
Tribhuvan University, Nepal
- Published
- 2024
9. Population pharmacokinetics of primaquine and its metabolites in African males.
- Author
-
Chotsiri, Palang, Mahamar, Almahamoudou, Diawara, Halimatou, Fasinu, Pius, Diarra, Kalifa, Sanogo, Koualy, Bousema, Teun, Walker, Larry, Brown, Joelle, Dicko, Alassane, Gosling, Roly, Chen, Ingrid, and Tarning, Joel
- Subjects
Carboxy-primaquine ,G6PD-deficiency ,Nonlinear mixed-effect model ,Pharmacokinetics ,Primaquine ,Primaquine carbamoyl-glucuronide ,Adolescent ,Adult ,Humans ,Male ,Middle Aged ,Young Adult ,Antimalarials ,Glucosephosphate Dehydrogenase Deficiency ,Primaquine - Abstract
BACKGROUND: Primaquine (PQ) is the prototype 8-aminoquinoline drug, a class which targets gametocytes and hypnozoites. The World Health Organization (WHO) recommends adding a single low dose of primaquine to the standard artemisinin-based combination therapy (ACT) in order to block malaria transmission in regions with low malaria transmission. However, the haemolytic toxicity is a major adverse outcome of primaquine in glucose-6-phosphate dehydrogenase (G6PD)-deficient subjects. This study aimed to characterize the pharmacokinetic properties of primaquine and its major metabolites in G6PD-deficient subjects. METHODS: A single low-dose of primaquine (0.4-0.5 mg/kg) was administered in twenty-eight African males. Venous and capillary plasma were sampled up to 24 h after the drug administration. Haemoglobin levels were observed up to 28 days after drug administration. Only PQ, carboxy-primaquine (CPQ), and primaquine carbamoyl-glucuronide (PQCG) were present in plasma samples and measured using liquid chromatography mass spectrometry. Drug and metabolites pharmacokinetic properties were investigated using nonlinear mixed-effects modelling. RESULTS: Population pharmacokinetic properties of PQ, CPQ, and PQCG can be described by one-compartment disposition kinetics with a transit-absorption model. Body weight was implemented as an allometric function on the clearance and volume parameters for all compounds. None of the covariates significantly affected the pharmacokinetic parameters. No significant correlations were detected between the exposures of the measured compounds and the change in haemoglobin or methaemoglobin levels. There was no significant haemoglobin drop in the G6PD-deficient patients after administration of a single low dose of PQ. CONCLUSIONS: A single low-dose of PQ was haematologically safe in this population of G6PD-normal and G6PD-deficient African males without malaria. Trial registration NCT02535767.
- Published
- 2024
10. A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)
- Published
- 2024
11. Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities
- Author
-
L'université de Thiès, Programme National de Lutte contre le Paludisme (PNLP), Senegal, Population Services International, Centers for Disease Control and Prevention, and US President's Malaria Initiative
- Published
- 2024
12. Controlled Human Malaria Infection Transmission Model - Phase A (CHMI-TransMod)
- Author
-
KEMRI-Wellcome Trust Collaborative Research Program, Sanaria Inc., and Kenya Medical Research Institute
- Published
- 2024
13. Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure
- Author
-
National Centre for Parasitology, Entomology and Malaria Control, Cambodia, Institut Pasteur du Cambodge, and David Serre, Professor
- Published
- 2024
14. A Study to Assess the Availability of Oral Primaquine and Its Inert Metabolite, Carboxyprimaquine, in the Body (PQcPQ)
- Author
-
Mahidol Oxford Tropical Medicine Research Unit and Faculty of Tropical Medicine, Mahidol University Bangkok, Thailand
- Published
- 2024
15. Efficacy of Focal Primaquine Mass Administration for Eliminating Plasmodium Vivax Malaria in Northern Myanmar
- Author
-
University of South Florida, Mahidol University, and Pyae Linn Aung, Secretary
- Published
- 2024
16. Tafenoquine and Primaquine in Colostrum and Breast Milk (TBM)
- Author
-
Mahidol Oxford Tropical Medicine Research Unit
- Published
- 2024
17. Primaquine Analysis in Pharmaceutical Formulation Using Multiple and Short‐End Injections by Capillary Zone Electrophoresis‐Ultraviolet Detection.
- Author
-
de Souza, Jéssica Cordeiro Queiroz, Chellini, Paula Rocha, de Souza, Marcus Vinícius Nora, and de Oliveira, Marcone Augusto Leal
- Subjects
- *
INJECTIONS , *HYDROCHLORIC acid , *QUALITY control , *PRIMAQUINE , *HYDROXYMETHYL compounds - Abstract
Novel methods were proposed for determining primaquine (PQN) in tablets by multiple‐injection capillary zone electrophoresis (MI‐CZE) and by short‐end injection CZE (SEI‐CZE), both with ultraviolet detection. The background electrolyte (BGE), consisting of 20 mmol/L of tris (hydroxymethyl) aminomethane and 30 mmol/L of hydrochloric acid at pH 2.0, was selected considering a comprehensive study involving the effective mobility versus pH curves of the analytes and BGE components. Experimental designs were applied in methods developments, showing the chemometric tool's applicability in achieving suitable electrophoretic conditions. A baseline resolution in the separation of adjacent peak pairs was obtained by injecting a spacer electrolyte for 18 s, with a voltage of + 15 kV, and the sample can be injected six consecutive times in a single run in less than 3 min, in the MI‐CZE method. For the SEI‐CZE method, the migration time of PQN was 0.6 min, and the method was applied to a demonstrative forced degradation study. Some validation parameters were evaluated for both methods, and all results were satisfactory, indicating that they can be implemented as PQN determination methods in routine quality control analyses. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. In vivo efficacy of chloroquine plus primaquine combination therapy against uncomplicated Plasmodium vivax malaria in Limu Kossa District, Jimma Zone, Southwest Ethiopia.
- Author
-
Asfaw, Wakgari, Bekele, Temesgen, Geshere, Geleta, Simma, Eba Alemayehu, Deressa, Chernet Tuge, and Ketema, Tsige
- Subjects
- *
PLASMODIUM vivax , *MALARIA , *TREATMENT failure , *TREATMENT effectiveness , *PLASMODIUM - Abstract
Background: Plasmodium vivax is the second most common malaria parasite in Ethiopia. It has been treated with chloroquine (CQ) for the past seven decades. However, the emergence of CQ-resistant strains in the nation urged the Federal Ministry of Health of Ethiopia to review its national malaria treatment guideline in 2018. In the revised guideline, the first-line treatment for uncomplicated P. vivax infection is a combination of CQ and primaquine (PQ). Thus, the present study was designed to evaluate the in vivo efficacy of CQ and PQ combination therapy against clinical P. vivax mono-infection in one of the malaria-endemic areas of Ethiopia. Methods: An open-label prospective clinical trial was conducted in the Limmu Kossa District, Jimma zone, Southwest Ethiopia, from September 2023 to March 2024. A total of 108 patients were recruited for the study. All participants received treatment with CQ at a dosage of 25 mg/kg over three days, followed by PQ at 0.25 mg/kg for 14 consecutive days. Patients were monitored for 42 days for any signs of treatment failure and malaria clinical symptoms, as per the World Health Organization (WHO) guidelines for anti-malarial drug evaluation. Additionally, haemoglobin (Hb) levels, body temperature, any adverse events, and signs of haemolysis were assessed. Data was analysed using R-software (version 4.0.0) and a significant level was considered at p < 0.05. Results: The median age of the patients was 23 years, ranging from 2.5 to 62 years. Of the 108 patients initially recruited, 100 completed the 42-day follow-up period. The combination therapy of CQ and PQ for uncomplicated clinical P. vivax malaria demonstrated excellent therapeutic efficacy, with a 100% cure rate observed at both day 28 and day 42. Additionally, the recommended low dose of PQ (0.25 mg/kg) was well-tolerated, with no signs of. Additionally, most common malaria symptoms were disappeared early in the follow-up period. Conclusion: The combination of CQ plus PQ has exhibited excellent efficacy against uncomplicated P. vivax malaria mono-infections. To preserve this efficacy, it is critical to ensure patients adhere to the full course of PQ treatment, despite its extended duration. Therefore, health authorities should put emphasis on the boosting of the public on the importance of finishing the prescribed medication regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. In vivo efficacy of chloroquine plus primaquine combination therapy against uncomplicated Plasmodium vivax malaria in Limu Kossa District, Jimma Zone, Southwest Ethiopia
- Author
-
Wakgari Asfaw, Temesgen Bekele, Geleta Geshere, Eba Alemayehu Simma, Chernet Tuge Deressa, and Tsige Ketema
- Subjects
Chloroquine ,Efficacy ,Ethiopia ,Limmu Kossa ,Jimma ,Primaquine ,Arctic medicine. Tropical medicine ,RC955-962 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Plasmodium vivax is the second most common malaria parasite in Ethiopia. It has been treated with chloroquine (CQ) for the past seven decades. However, the emergence of CQ-resistant strains in the nation urged the Federal Ministry of Health of Ethiopia to review its national malaria treatment guideline in 2018. In the revised guideline, the first-line treatment for uncomplicated P. vivax infection is a combination of CQ and primaquine (PQ). Thus, the present study was designed to evaluate the in vivo efficacy of CQ and PQ combination therapy against clinical P. vivax mono-infection in one of the malaria-endemic areas of Ethiopia. Methods An open-label prospective clinical trial was conducted in the Limmu Kossa District, Jimma zone, Southwest Ethiopia, from September 2023 to March 2024. A total of 108 patients were recruited for the study. All participants received treatment with CQ at a dosage of 25 mg/kg over three days, followed by PQ at 0.25 mg/kg for 14 consecutive days. Patients were monitored for 42 days for any signs of treatment failure and malaria clinical symptoms, as per the World Health Organization (WHO) guidelines for anti-malarial drug evaluation. Additionally, haemoglobin (Hb) levels, body temperature, any adverse events, and signs of haemolysis were assessed. Data was analysed using R-software (version 4.0.0) and a significant level was considered at p
- Published
- 2024
- Full Text
- View/download PDF
20. Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis.
- Author
-
Adissu, Wondimagegn, Brito, Marcelo, Garbin, Eduardo, Macedo, Marcela, Monteiro, Wuelton, Mukherjee, Sandip, Myburg, Jane, Alam, Mohammad, Bancone, Germana, Bansil, Pooja, Pal, Sampa, Sharma, Abhijit, Zobrist, Stephanie, Bryan, Andrew, Chu, Cindy, Das, Santasabuj, Domingo, Gonzalo, Hann, Amanda, Kublin, James, Lacerda, Marcus, Layton, Mark, Ley, Benedikt, Murphy, Sean, Nosten, Francois, Pereira, Dhélio, Price, Ric, Talukdar, Arunansu, Yilma, Daniel, and Gerth-Guyette, Emily
- Subjects
Female ,Humans ,Primaquine ,Glucosephosphate Dehydrogenase Deficiency ,Retrospective Studies ,Antimalarials ,Malaria ,Vivax - Abstract
INTRODUCTION: Screening for G6PD deficiency can inform disease management including malaria. Treatment with the antimalarial drugs primaquine and tafenoquine can be guided by point-of-care testing for G6PD deficiency. METHODS AND FINDINGS: Data from similar clinical studies evaluating the performance of the STANDARD G6PD Test (SD Biosensor, South Korea) conducted in Bangladesh, Brazil, Ethiopia, India, Thailand, the United Kingdom, and the United States were pooled. Test performance was assessed in a retrospective analysis on capillary and venous specimens. All study sites used spectrophotometry for reference G6PD testing, and either the HemoCue or complete blood count for reference hemoglobin measurement. The sensitivity of the STANDARD G6PD Test using the manufacturer thresholds for G6PD deficient and intermediate cases in capillary specimens from 4212 study participants was 100% (95% Confidence Interval (CI): 97.5%-100%) for G6PD deficient cases with 60% on the reference assay. The negative predictive value for females with G6PD activity >60% was 99.6% (95% CI 99.1%-99.8%) on capillary specimens. Sensitivity among 396 P. vivax malaria cases was 100% (69.2%-100.0%) for both deficient and intermediate cases. Across the full dataset, 37% of those classified as G6PD deficient or intermediate resulted from true normal cases. Despite this, over 95% of cases would receive correct treatment with primaquine, over 87% of cases would receive correct treatment with tafenoquine, and no true G6PD deficient cases would be treated inappropriately based on the result of the STANDARD G6PD Test. CONCLUSIONS: The STANDARD G6PD Test enables safe access to drugs which are contraindicated for individuals with G6PD deficiency. Operational considerations will inform test uptake in specific settings.
- Published
- 2023
21. A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh
- Author
-
International Centre for Diarrhoeal Disease Research, Bangladesh
- Published
- 2024
22. Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy
- Author
-
US Army Medical Research Directorate-Africa - Walter Reed Army Institute of Research, GlaxoSmithKline, Kenya Medical Research Institute, FHI Clinical SA Proprietary Limited, and DF/Net
- Published
- 2024
23. Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield (CUREMA)
- Author
-
Oswaldo Cruz Foundation
- Published
- 2024
24. Addressing health equity for breastfeeding women: primaquine for Plasmodium vivax radical cure
- Author
-
Nada Abla, Anne Claire Marrast, Elodie Jambert, Naomi Richardson, Stephan Duparc, Lisa Almond, Karen Rowland Yeo, Xian Pan, Joel Tarning, Ping Zhao, Janice Culpepper, Catriona Waitt, Charlotte Koldeweij, Susan Cole, Andrew S. Butler, Sonia Khier, Jörg J. Möhrle, and Myriam El Gaaloul
- Subjects
Plasmodium vivax ,Radical cure ,Primaquine ,Physiologically-based pharmacokinetic modelling ,Breastfeeding ,Pregnancy ,Arctic medicine. Tropical medicine ,RC955-962 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Plasmodium vivax malaria remains a global health challenge, with approximately 6.9 million estimated cases in 2022. The parasite has a dormant liver stage, the hypnozoite, which reactivates to cause repeated relapses over weeks, months, or years. These relapses erode patient health, contribute to the burden of malaria, and promote transmission. Radical cure to prevent relapses requires administration of an 8-aminoquinoline, either primaquine or tafenoquine. However, malaria treatment guidelines updated by the World Health Organization (WHO) in October 2023 restrict primaquine use for women breastfeeding children
- Published
- 2024
- Full Text
- View/download PDF
25. The effect of single low-dose primaquine treatment for uncomplicated Plasmodium falciparum malaria on haemoglobin levels in Ethiopia: a longitudinal cohort study
- Author
-
Kassahun Habtamu, Hallelujah Getachew, Ashenafi Abossie, Assalif Demissew, Arega Tsegaye, Teshome Degefa, Xiaoming Wang, Ming-Chieh Lee, Guofa Zhou, Solomon Kibret, Christopher L. King, James W. Kazura, Beyene Petros, Delenasaw Yewhalaw, and Guiyun Yan
- Subjects
Plasmodium falciparum ,Malaria elimination ,Primaquine ,Artemisinin-based combination therapies ,Haemoglobin ,G6PD deficiency ,Arctic medicine. Tropical medicine ,RC955-962 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background To interrupt residual malaria transmission and achieve successful elimination of Plasmodium falciparum in low-transmission settings, the World Health Organization (WHO) recommends the administration of a single dose of 0.25 mg/kg (or 15 mg/kg for adults) primaquine (PQ) combined with artemisinin-based combination therapy (ACT), without glucose-6-phosphate dehydrogenase (G6PD) testing. However, due to the risk of haemolysis in patients with G6PD deficiency (G6PDd), PQ use is uncommon. Thus, this study aimed to assess the safety of a single low dose of PQ administered to patients with G6PD deficiency. Methods An observational cohort study was conducted with patients treated for uncomplicated P. falciparum malaria with either single-dose PQ (0.25 mg/kg) (SLD PQ) + ACT or ACT alone. Microscopy-confirmed uncomplicated P. falciparum malaria patients visiting public health facilities in Arjo Didessa, Southwest Ethiopia, were enrolled in the study from September 2019 to November 2022. Patients with uncomplicated P. falciparum malaria were followed up for 28 days through clinical and laboratory diagnosis, such as measurements of G6PD levels and haemoglobin (Hb) concentrations. G6PD levels were measured by a quantiative CareSTART™ POCT S1 biosensor machine. Patient interviews were also conducted, and the type and frequency of clinical complaints were recorded. Hb data were taken on days (D) 7, 14, 21, and 28 following treatment with SLD-PQ + ACT or ACT alone. Results A total of 249 patients with uncomplicated P. falciparum malaria were enrolled in this study. Of these, 83 (33.3%) patients received ACT alone, and 166 (66.7%) received ACT combined with SLD-PQ treatment. The median age of the patients was 20 (IQR 28–15) years. G6PD deficiency was found in 17 (6.8%) patients, 14 males and 3 females. There were 6 (7.2%) and 11 (6.6%) phenotypic G6PD-deficient patients in the ACT alone and ACT + SLD-PQ arms, respectively. The mean Hb levels in patients treated with ACT + SLD-PQ were reduced by an average of 0.45 g/dl (95% CI = 0.39 to 0.52) in the posttreatment phase (D7) compared to a reduction of 0.30 g/dl (95% CI = 0.14 to − 0.47) in patients treated with ACT alone (P = 0.157). A greater mean Hb reduction was observed on day 7 in the G6PDd ACT + SLD-PQ group (− 0.60 g/dL) than in the G6PDd ACT alone group (− 0.48 g/dL); however, there was no statistically significant difference (P = 0.465). Overall, D14 losses were 0.10 g/dl (95% CI = − 0.00 to 0.20) and 0.05 g/dl (95% CI = − 0.123 to 0.22) in patients with and without SLD-PQ, respectively (P = 0.412). Conclusions This study’s findings indicate that using SLD-PQ in combination with ACT is safe for uncomplicated P. falciparum malaria regardless of the patient's G6PD status in Ethiopian settings. Caution should be taken in extrapolating this finding in other settings with diverse G6DP phenotypes.
- Published
- 2024
- Full Text
- View/download PDF
26. Efficacy and safety of chloroquine plus primaquine for the treatment of Plasmodium vivax malaria in Hamusit site, Northwestern Ethiopia
- Author
-
Habtamu Gebrie, Mulat Yimer, Animen Ayehu, Hussien Mohammed, Henok Hailgiorgis, Yonas Wuletaw, Mesay Hailu, Getachew Tolera, Geremew Tasew, Mogess Kassa, and Bokretsion Gidey
- Subjects
Chloroquine ,Drug efficacy ,Ethiopia ,Plasmodium vivax ,Primaquine ,Arctic medicine. Tropical medicine ,RC955-962 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Plasmodium vivax malaria is still an important public health problem in Ethiopia. Unlike Plasmodium falciparum, P. vivax has a dormant liver stage (hypnozoite) that can be a risk of recurrent vivax malaria unless treated by radical cure with primaquine. Drug resistance to chloroquine is threatening malaria control and elimination efforts. This study assessed the therapeutic efficacy and safety of chloroquine plus 14 days of primaquine on P. vivax infection based on parasitological, clinical, and haematological parameters. Methods A single-arm in vivo prospective therapeutic efficacy study was conducted to assess the clinical and parasitological response to the first-line treatment of P. vivax in Ethiopia, chloroquine plus 14 days low dose of (0.25 mg/kg/day) primaquine between December 2022 and March 2023 at Hamusit Health Centre using the standard World Health Organization (WHO) protocol. A total of 100 study participants with P. vivax mono-infection who were over 6 months old were enrolled and monitored for adequate clinical and parasitological responses for 42 days. The WHO double-entry Excel sheet and SPSS v.25 software were used for Kaplan–Meier survival analysis, and a paired t-test was used for analysis of haemoglobin improvements between follow up days. Results A total of 100 patients were enrolled among those, 96% cases were rural residents, 93% had previous malaria exposure, and predominant age group was 5–15 years (61%). 92.6% (95% CI 85.1–96.4%) of enrolled patients were adequate clinical and parasitological response, and 7.4% (95% CI 3.6–14.9%) recurrences were observed among treated patients. The fever and parasite clearance rate on day 3 were 98% and 94%, respectively. The baseline haemoglobin levels improved significantly compared to those days 14 and 42 (p
- Published
- 2024
- Full Text
- View/download PDF
27. Addressing health equity for breastfeeding women: primaquine for Plasmodium vivax radical cure.
- Author
-
Abla, Nada, Marrast, Anne Claire, Jambert, Elodie, Richardson, Naomi, Duparc, Stephan, Almond, Lisa, Rowland Yeo, Karen, Pan, Xian, Tarning, Joel, Zhao, Ping, Culpepper, Janice, Waitt, Catriona, Koldeweij, Charlotte, Cole, Susan, Butler, Andrew S., Khier, Sonia, Möhrle, Jörg J., and El Gaaloul, Myriam
- Subjects
- *
WOMEN'S health , *PLASMODIUM vivax , *MATERNAL exposure , *DISEASE relapse , *BREAST milk - Abstract
Plasmodium vivax malaria remains a global health challenge, with approximately 6.9 million estimated cases in 2022. The parasite has a dormant liver stage, the hypnozoite, which reactivates to cause repeated relapses over weeks, months, or years. These relapses erode patient health, contribute to the burden of malaria, and promote transmission. Radical cure to prevent relapses requires administration of an 8-aminoquinoline, either primaquine or tafenoquine. However, malaria treatment guidelines updated by the World Health Organization (WHO) in October 2023 restrict primaquine use for women breastfeeding children < 6 months of age, or women breastfeeding older children if their child is G6PD deficient or if the child's G6PD status is unknown. Primaquine restrictions assume that 8-aminoquinoline exposures in breast milk would be sufficient to cause haemolysis in the nursing infant should they be G6PD deficient. WHO recommendations for tafenoquine are awaited. Notably, the WHO recommends that infants are breastfed for the first 2 years of life, and exclusively until 6 months old. Repeated pregnancies, followed by extended breastfeeding leaves women in P. vivax endemic regions potentially vulnerable to relapses for many years. This puts women's health at risk, increases the malaria burden, and perpetuates transmission, hindering malaria control and elimination. The benefits of lifting restrictions on primaquine administration to breastfeeding women are significant, avoiding the adverse consequences of repeated episodes of acute malaria, such as severe anaemia. Recent data challenge the restriction of primaquine in breastfeeding women. Clinical pharmacokinetic data in breastfeeding infants ≥ 28 days old show that the exposure to primaquine is very low and less than 1% of the maternal exposure, indicating negligible risk to infants, irrespective of their G6PD status. Physiologically-based pharmacokinetic modelling complements the clinical data, predicting minimal primaquine exposure to infants and neonates via breast milk from early post-partum. This article summarizes the clinical and modelling evidence for a favourable benefit:risk evaluation of P. vivax radical cure with primaquine for breastfeeding women without the need for infant G6PD testing, supporting a change in policy. This adjustment to current treatment guidelines would support health equity in regard to effective interventions to protect women and their children, enhance malaria control strategies, and advance P. vivax elimination. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Linked-evidence modelling of qualitative G6PD testing to inform low- and intermediate-dose primaquine treatment for radical cure of Plasmodium vivax.
- Author
-
Gatton, Michelle L.
- Subjects
- *
GLUCOSE-6-phosphate dehydrogenase , *PLASMODIUM vivax , *MALARIA prevention , *GLUCOSE-6-phosphate dehydrogenase deficiency , *PRIMAQUINE - Abstract
Background: Radical cure of Plasmodium vivax infections is key to the control of vivax malaria. However, the standard doses of 8-aminoquinoline drugs used for radical cure can cause severe haemolysis in G6PD-deficient patients. The availability of near-patient G6PD tests could increase use of primaquine (PQ), however direct evidence of the impacts that G6PD testing has on downstream patient outcomes, such as haemolysis and recurrence is lacking. Methodology/Principle findings: A linked-evidence model was created to investigate changes in the number of severe haemolysis events and P. vivax recurrences within 6 months of treatment when qualitative G6PD testing was used to guide PQ treatment (0.25mg/kg/day for 14 days and 0.5mg/kg/day for 7 days), compared to prescribing 14-day PQ with no G6PD testing. In the model patients identified as G6PD-deficient received 8-week PQ (0.75mg/kg/week). The model was used to simulate scenarios with 1%, 5% and 10% prevalence of G6PD-deficiency (G6PDd) in theoretical populations of 10,000 male and female P. vivax patients and initially assumed 100% adherence to the prescribed PQ regiment. Results illustrate that G6PD testing to guide the 14-day PQ regiment reduced severe haemolysis by 21–80% and increased recurrences by 3–6%, compared to applying the 14-day PQ regiment without G6PD testing. Results for the 7-day PQ regiment informed by G6PD testing were mixed, dependent on G6PDd prevalence and sex. When adherence to the PQ regiments was less than perfect the model predicted reductions in the number of recurrences at all prevalence levels, provided adherence to 7-day PQ was 5–10% higher than adherence to the 14-day regiment. Conclusions/Significance: Introduction of G6PD testing to guide PQ treatment reduces severe haemolysis events for the 14-day regiment, and the 7-day regiment in higher G6PDd prevalence settings, compared to use of 14-day PQ without G6PD testing when all patients adhere to the prescribed PQ treatment. At a population level, there were increases in recurrences, but this could be resolved when the 7-day regiment was used and had superior adherence compared to the 14-day regiment. Author summary: To eliminate vivax malaria treatment is required that cures the blood infection and also kills any dormant parasites in the liver (called hypnozoites). Unfortunately, drugs currently available to treat hypnozoites such as primaquine can cause severe haemolysis when given to patients who have glucose-6-phosphate dehydrogenase (G6PD) deficiency, a common human enzyme polymorphism. The author created a mathematical model that compares the number of severe haemolysis events and vivax recurrences within 6 months of treatment in a theoretical population when qualitative G6PD tests are used to guide primaquine treatment versus the use of primaquine without consideration of the G6PD status of the patient. The results demonstrate that adding G6PD tests into the clinical pathway can reduce the number of severe haemolysis events, but may increase the number of recurrences, with specific results determined by the prevalence of G6PD deficiency, the dosing regiment and adherence to the prescribed primaquine treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Targeted polymeric primaquine nanoparticles: optimization, evaluation, and in-vivo liver uptake for improved malaria treatment.
- Author
-
Bhargava, Sarvesh, Dewangan, Hitesh Kumar, and Deshmukh, Rohitas
- Abstract
AbstractPrimaquine (PQ) is a widely used antimalarial drug, but its high dosage requirements can lead to significant tissue damage and adverse gastrointestinal and hematological effects. Recent studies have shown that nanoformulations can enhance the bioavailability of pharmaceuticals, thereby increasing efficacy, reducing dosing frequency, and minimizing toxicity. In this study, PQ-loaded PLGA nanoparticles (PQ-NPs) were prepared using a modified double emulsion solvent evaporation technique (w/o/w). The PQ-NPs exhibited a mean particle size of 228 ± 2.6 nm, a zeta potential of +27.4 mV, and an encapsulation efficiency of 81.3 ± 3.5%. Scanning electron microscopy (SEM) confirmed their spherical morphology, and the
in vitro release profile demonstrated continuous drug release over 72 h. Differential scanning calorimetry (DSC) thermograms indicated that the drug was present in the nanoparticles, with improved physical stability. Fourier-transform infrared spectroscopy (FTIR) analysis showed no interactions between the various substances in the NPs.In vivo studies in Swiss albino mice infected withPlasmodium berghei revealed that the nanoformulated PQ was 20% more effective than the standard oral dose. Biodistribution studies indicated that 80% of the NPs accumulated in the liver, highlighting their potential for targeted drug delivery. This research demonstrates the successful development of a nanomedicine delivery system for antimalarial drugs, offering a promising strategy to enhance treatment efficacy while reducing adverse effects. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
30. Efficacy and safety of chloroquine plus primaquine for the treatment of Plasmodium vivax malaria in Hamusit site, Northwestern Ethiopia.
- Author
-
Gebrie, Habtamu, Yimer, Mulat, Ayehu, Animen, Mohammed, Hussien, Hailgiorgis, Henok, Wuletaw, Yonas, Hailu, Mesay, Tolera, Getachew, Tasew, Geremew, Kassa, Mogess, and Gidey, Bokretsion
- Subjects
- *
PLASMODIUM vivax , *CHLOROQUINE , *PRIMAQUINE , *MALARIA , *PLASMODIUM falciparum - Abstract
Background: Plasmodium vivax malaria is still an important public health problem in Ethiopia. Unlike Plasmodium falciparum, P. vivax has a dormant liver stage (hypnozoite) that can be a risk of recurrent vivax malaria unless treated by radical cure with primaquine. Drug resistance to chloroquine is threatening malaria control and elimination efforts. This study assessed the therapeutic efficacy and safety of chloroquine plus 14 days of primaquine on P. vivax infection based on parasitological, clinical, and haematological parameters. Methods: A single-arm in vivo prospective therapeutic efficacy study was conducted to assess the clinical and parasitological response to the first-line treatment of P. vivax in Ethiopia, chloroquine plus 14 days low dose of (0.25 mg/kg/day) primaquine between December 2022 and March 2023 at Hamusit Health Centre using the standard World Health Organization (WHO) protocol. A total of 100 study participants with P. vivax mono-infection who were over 6 months old were enrolled and monitored for adequate clinical and parasitological responses for 42 days. The WHO double-entry Excel sheet and SPSS v.25 software were used for Kaplan–Meier survival analysis, and a paired t-test was used for analysis of haemoglobin improvements between follow up days. Results: A total of 100 patients were enrolled among those, 96% cases were rural residents, 93% had previous malaria exposure, and predominant age group was 5–15 years (61%). 92.6% (95% CI 85.1–96.4%) of enrolled patients were adequate clinical and parasitological response, and 7.4% (95% CI 3.6–14.9%) recurrences were observed among treated patients. The fever and parasite clearance rate on day 3 were 98% and 94%, respectively. The baseline haemoglobin levels improved significantly compared to those days 14 and 42 (p < 0.001). No serious adverse event was observed during the study period. Conclusions: In this study, co-administration of chloroquine with primaquine was efficacious and well-tolerated with fast resolution of fever and high parasites clearance rate. However, the 7.4% failure is reported is alarming that warrant further monitoring of the therapeutic efficacy study of P. vivax. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Burden and clinical characteristics of recurrent Plasmodium vivax infections, and impact of primaquine for radical cure: a systematic scoping review in India
- Author
-
Loick Pradel Kojom Foko and Vineeta Singh
- Subjects
epidemiology ,India ,Plasmodium vivax ,primaquine ,recurrent infections ,Infectious and parasitic diseases ,RC109-216 - Abstract
BackgroundIndia accounts for the bulk of Plasmodium vivax burden in South East Asia. Primaquine (PQ) is the only currently available drug for treating relapses in P. vivax malaria. MethodsHere, we provide an overview of the epidemiology and clinical characteristics of P. vivax recurrent infections in India and discuss current knowledge gaps and priority research areas for further investigations, with emphasis on relapses and their radical cure with PQ. Results and discussionA total of 27 studies involving ~27,000 P. vivax infected patients were finally included. Recurrent infections with P. vivax malaria are common, especially in young males. The burden of P. vivax relapse greatly varies across Indian regions, with a proportion range of 1.47 to 6% based on the included studies which all used low (very low) PQ dose. There is a need for more empirical data on the effectiveness and safety of weekly administration of PQ at 0.75 mg/Kg for eight weeks in G6PD–deficiency patients in India, especially in children. Further research priorities should also be focused on the epidemiology of confounding factor, such as CQ-resistance, mixed infections, or Pv genetic diversity are needed. The clinical impact of P. vivax relapses (e.g., severe malaria, mortality) is also of valuable interest in upcoming studies. More studies addressing the above-mentioned missing links should be implemented to inform malariologists, clinicians, populations, and policy makers on real situation of P. vivax relapses and the clinical impact of PQ in India. All taken together, these would have important implications for P. vivax malaria control and elimination in endemic areas.
- Published
- 2024
- Full Text
- View/download PDF
32. Unmasking hidden risks: A case of primaquine-induced intravascular hemolysis in G-6-PD deficient malaria patient
- Author
-
Tanatorn Soravipukuntorn, Pathomthep Leowattana, Katawut Panyatanakun, Rachata Charoenwisedsil, Borimas Hanboonkunupakarn, Srivicha Krudsood, and Wasin Matsee
- Subjects
Hemolytic crisis ,G-6-PD deficiency ,Primaquine ,Plasmodium vivax ,Relapse ,Arctic medicine. Tropical medicine ,RC955-962 ,Infectious and parasitic diseases ,RC109-216 - Published
- 2024
- Full Text
- View/download PDF
33. Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru
- Author
-
Universidad Peruana Cayetano Heredia, UNITAID, and ICON plc
- Published
- 2023
34. Clinical Investigation Study to Evaluate the Consistency and Reproducibility of Two Consecutive Mosquito Feeding Assays
- Author
-
Walter Reed Army Institute of Research (WRAIR) and Kenya Medical Research Institute
- Published
- 2023
35. Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas (PRIMA)
- Author
-
International Centre for Diarrhoeal Disease Research, Bangladesh, Tribhuvan University, Nepal, Arba Minch University, and Addis Ababa University
- Published
- 2023
36. Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand (ARCTIC)
- Author
-
Medicines for Malaria Venture and Dr. Prayuth Sudathip, Deputy Director, DVBD
- Published
- 2023
37. Enhanced Ca2+-Dependent SK-Channel Gating and Membrane Trafficking in Human Atrial Fibrillation
- Author
-
Heijman, Jordi, Zhou, Xiaobo, Morotti, Stefano, Molina, Cristina E, Abu-Taha, Issam H, Tekook, Marcel, Jespersen, Thomas, Zhang, Yiqiao, Dobrev, Shokoufeh, Milting, Hendrik, Gummert, Jan, Karck, Matthias, Kamler, Markus, El-Armouche, Ali, Saljic, Arnela, Grandi, Eleonora, Nattel, Stanley, and Dobrev, Dobromir
- Subjects
Medical Physiology ,Biomedical and Clinical Sciences ,Cardiovascular ,Heart Disease ,Aetiology ,5.1 Pharmaceuticals ,2.1 Biological and endogenous factors ,Development of treatments and therapeutic interventions ,Animals ,Humans ,Atrial Fibrillation ,Apamin ,Primaquine ,Calmodulin ,Heart Atria ,Myocytes ,Cardiac ,Anti-Arrhythmia Agents ,Action Potentials ,Small-Conductance Calcium-Activated Potassium Channels ,actinin ,apamin ,atrial fibrillation ,atrial remodeling ,calmodulin ,protein phosphatase-2A ,protein transport ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundSmall-conductance Ca2+-activated K+ (SK)-channel inhibitors have antiarrhythmic effects in animal models of atrial fibrillation (AF), presenting a potential novel antiarrhythmic option. However, the regulation of SK-channels in human atrial cardiomyocytes and its modification in patients with AF are poorly understood and were the object of this study.MethodsApamin-sensitive SK-channel current (ISK) and action potentials were recorded in human right-atrial cardiomyocytes from sinus rhythm control (Ctl) patients or patients with (long-standing persistent) chronic AF (cAF).ResultsISK was significantly higher, and apamin caused larger action potential prolongation in cAF- versus Ctl-cardiomyocytes. Sensitivity analyses in an in silico human atrial cardiomyocyte model identified IK1 and ISK as major regulators of repolarization. Increased ISK in cAF was not associated with increases in mRNA/protein levels of SK-channel subunits in either right- or left-atrial tissue homogenates or right-atrial cardiomyocytes, but the abundance of SK2 at the sarcolemma was larger in cAF versus Ctl in both tissue-slices and cardiomyocytes. Latrunculin-A and primaquine (anterograde and retrograde protein-trafficking inhibitors) eliminated the differences in SK2 membrane levels and ISK between Ctl- and cAF-cardiomyocytes. In addition, the phosphatase-inhibitor okadaic acid reduced ISK amplitude and abolished the difference between Ctl- and cAF-cardiomyocytes, indicating that reduced calmodulin-Thr80 phosphorylation due to increased protein phosphatase-2A levels in the SK-channel complex likely contribute to the greater ISK in cAF-cardiomyocytes. Finally, rapid electrical activation (5 Hz, 10 minutes) of Ctl-cardiomyocytes promoted SK2 membrane-localization, increased ISK and reduced action potential duration, effects greatly attenuated by apamin. Latrunculin-A or primaquine prevented the 5-Hz-induced ISK-upregulation.ConclusionsISK is upregulated in patients with cAF due to enhanced channel function, mediated by phosphatase-2A-dependent calmodulin-Thr80 dephosphorylation and tachycardia-dependent enhanced trafficking and targeting of SK-channel subunits to the sarcolemma. The observed AF-associated increases in ISK, which promote reentry-stabilizing action potential duration shortening, suggest an important role for SK-channels in AF auto-promotion and provide a rationale for pursuing the antiarrhythmic effects of SK-channel inhibition in humans.
- Published
- 2023
38. Bioequivalence of a new coated 15 mg primaquine formulation for malaria elimination
- Author
-
Julie Nguyen Ngoc Pouplin, Thoopmanee Kaendiao, Bilal Ahmad Rahimi, Mayur Soni, Hensi Basopia, Darshana Shah, Jitendra Patil, Vyom Dholakia, Yash Suthar, Joel Tarning, Mavuto Mukaka, and Walter R. Taylor
- Subjects
Primaquine ,Bioequivalence ,Malaria ,Pharmacokinetics ,Arctic medicine. Tropical medicine ,RC955-962 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background With only one 15 mg primaquine tablet registered by a stringent regulatory authority and marketed, more quality-assured primaquine is needed to meet the demands of malaria elimination. Methods A classic, two sequence, crossover study, with a 10-day wash out period, of 15 mg of IPCA-produced test primaquine tablets and 15 mg of Sanofi reference primaquine tablets was conducted. Healthy volunteers, aged 18–45 years, without glucose-6-phosphate dehydrogenase deficiency, a baseline haemoglobin ≥ 11 g/dL, creatinine clearance ≥ 70 mL/min/1.73 ms, and body mass index of 18.5–30 kg/m2 were randomized to either test or reference primaquine, administered on an empty stomach with 240 mL of water. Plasma primaquine and carboxyprimaquine concentrations were measured at baseline, then 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.333, 2.667, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0 and 72.0 h by liquid chromatography coupled to tandem mass spectrometry. Primaquine pharmacokinetic profiles were evaluated by non-compartmental analysis and bioequivalence concluded if the 90% confidence intervals (CI) of geometric mean (GM) ratios of test vs. reference formulation for the peak concentrations (C max) and area under the drug concentration–time (AUC0–t) were within 80.00 to 125.00%. Results 47 of 50 volunteers, median age 33 years, completed both dosing rounds and were included in the bioequivalence analysis. For primaquine, GM C max values for test and reference formulations were 62.12 vs. 59.63 ng/mL, resulting in a GM ratio (90% CI) of 104.17% (96.92–111.96%); the corresponding GM AUC0–t values were 596.56 vs. 564.09 ngxh/mL, for a GM ratio of 105.76% (99.76–112.08%). Intra-subject coefficient of variation was 20.99% for C max and 16.83% for AUC0–t. Median clearances and volumes of distribution were similar between the test and reference products: 24.6 vs. 25.2 L/h, 189.4 vs. 191.0 L, whilst the median half-lives were the same, 5.2 h. Conclusion IPCA primaquine was bioequivalent to the Sanofi primaquine. This opens the door to prequalification, registration in malaria endemic countries, and programmatic use for malaria elimination. Trial registration The trial registration reference is ISRCTN 54640699
- Published
- 2024
- Full Text
- View/download PDF
39. Population pharmacokinetics of primaquine and its metabolites in African males
- Author
-
Palang Chotsiri, Almahamoudou Mahamar, Halimatou Diawara, Pius S. Fasinu, Kalifa Diarra, Koualy Sanogo, Teun Bousema, Larry A. Walker, Joelle M. Brown, Alassane Dicko, Roly Gosling, Ingrid Chen, and Joel Tarning
- Subjects
Primaquine ,Carboxy-primaquine ,Primaquine carbamoyl-glucuronide ,Pharmacokinetics ,Nonlinear mixed-effect model ,G6PD-deficiency ,Arctic medicine. Tropical medicine ,RC955-962 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Primaquine (PQ) is the prototype 8-aminoquinoline drug, a class which targets gametocytes and hypnozoites. The World Health Organization (WHO) recommends adding a single low dose of primaquine to the standard artemisinin-based combination therapy (ACT) in order to block malaria transmission in regions with low malaria transmission. However, the haemolytic toxicity is a major adverse outcome of primaquine in glucose-6-phosphate dehydrogenase (G6PD)-deficient subjects. This study aimed to characterize the pharmacokinetic properties of primaquine and its major metabolites in G6PD-deficient subjects. Methods A single low-dose of primaquine (0.4–0.5 mg/kg) was administered in twenty-eight African males. Venous and capillary plasma were sampled up to 24 h after the drug administration. Haemoglobin levels were observed up to 28 days after drug administration. Only PQ, carboxy-primaquine (CPQ), and primaquine carbamoyl-glucuronide (PQCG) were present in plasma samples and measured using liquid chromatography mass spectrometry. Drug and metabolites’ pharmacokinetic properties were investigated using nonlinear mixed-effects modelling. Results Population pharmacokinetic properties of PQ, CPQ, and PQCG can be described by one-compartment disposition kinetics with a transit-absorption model. Body weight was implemented as an allometric function on the clearance and volume parameters for all compounds. None of the covariates significantly affected the pharmacokinetic parameters. No significant correlations were detected between the exposures of the measured compounds and the change in haemoglobin or methaemoglobin levels. There was no significant haemoglobin drop in the G6PD-deficient patients after administration of a single low dose of PQ. Conclusions A single low-dose of PQ was haematologically safe in this population of G6PD-normal and G6PD-deficient African males without malaria. Trial registration NCT02535767
- Published
- 2024
- Full Text
- View/download PDF
40. Kinetics of glucose-6-phosphate dehydrogenase (G6PD) activity during Plasmodium vivax infection: implications for early radical malaria treatment
- Author
-
Laureen Dahuron, Juste Goungounga, Moustapha Drame, Maylis Douine, Mathieu Nacher, Théo Blaise, Emilie Mosnier, Lise Musset, Marie Fouillet, Félix Djossou, and Loïc Epelboin
- Subjects
Plasmodium vivax ,G6PD/Glucose-6-phosphase dehydrogenase ,Malaria ,Primaquine ,French Guiana ,Arctic medicine. Tropical medicine ,RC955-962 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Plasmodium vivax relapses due to dormant liver hypnozoites can be prevented with primaquine. However, the dose must be adjusted in individuals with glucose-6-phosphate-dehydrogenase (G6PD) deficiency. In French Guiana, assessment of G6PD activity is typically delayed until day (D)14 to avoid the risk if misclassification. This study assessed the kinetics of G6PD activity throughout P. vivax infection to inform the timing of treatment. Methods For this retrospective monocentric study, data on G6PD activity between D1 and D28 after treatment initiation with chloroquine or artemisinin-based combination therapy were collected for patients followed at Cayenne Hospital, French Guiana, between January 2018 and December 2020. Patients were divided into three groups based on the number of available G6PD activity assessments: (i) at least two measurements during the P. vivax malaria infection; (ii) two measurements: one during the current infection and one previously; (iii) only one measurement during the malaria infection. Results In total, 210 patients were included (80, 20 and 110 in groups 1, 2 and 3, respectively). Data from group 1 showed that G6PD activity remained stable in each patient over time (D1, D3, D7, D14, D21, D28). None of the patients with normal G6PD activity during the initial phase (D1–D3) of the malaria episode (n = 44) was categorized as G6PD-deficient at D14. Patients with G6PD activity
- Published
- 2024
- Full Text
- View/download PDF
41. Therapeutic Efficacy of Chloroquine Plus Primaquine in the Treatment of Uncomplicated Plasmodium Vivax (CQ+PQ)
- Author
-
Ethiopian Public Health Institute and Dinka Dugassa, Principal Investigator
- Published
- 2023
42. Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua (MCMPFPB)
- Author
-
Cipto Mangunkusumo Hospital, PT Natura Nuswantara Nirmala, and Syamsudin Abdillah,Ph.D, Pharm D, Profesor Dr Syamsudin Abdillah, M.Biomed
- Published
- 2023
43. TES of Chloroquine for Pv in the Philippines in 2016 (TES)
- Author
-
World Health Organization and Fe Espino, Principal Investigator, Head of Parasitology Department
- Published
- 2023
44. TES of Artemether-lumefantrine for Pf in the Philippines in 2015 (TES)
- Author
-
World Health Organization and Fe Espino, Medical Specialist IV / Head of Parasitology Department / Principal Investigator
- Published
- 2023
45. TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)
- Author
-
World Health Organization and Fe Espino, Principal Investigator, Head of Parasitology Department
- Published
- 2023
46. TES of Artemether-lumefantrine for Pf in the Philippines in 2017-2018 (TES)
- Author
-
World Health Organization and Fe Espino, Medical Specialist IV, Principal Investigator, Head of Parasitology Department
- Published
- 2023
47. Factors hindering coverage of targeted mass treatment with primaquine in a malarious township of northern Myanmar in 2019–2020
- Author
-
Aung, Pyae Linn, Soe, Myat Thu, Soe, Than Naing, Oo, Thit Lwin, Win, Kyawt Mon, Cui, Liwang, Kyaw, Myat Phone, Sattabongkot, Jetsumon, Okanurak, Kamolnetr, and Parker, Daniel M
- Subjects
Rare Diseases ,Clinical Research ,Good Health and Well Being ,Male ,Child ,Humans ,Child ,Preschool ,Primaquine ,Antimalarials ,Cross-Sectional Studies ,Myanmar ,Glucosephosphate Dehydrogenase Deficiency ,Malaria ,Vivax - Abstract
Targeted mass primaquine treatment (TPT) might be an effective intervention to facilitate elimination of vivax malaria in Myanmar by 2030. In this study, we explored the factors hindering coverage of a TPT campaign conducted in a malarious township of northern Myanmar. From August 2019 to July 2020, a cross-sectional exploratory design including quantitative and qualitative data was conducted in five villages with high P. vivax prevalence following a TPT campaign. Among a targeted population of 2322; 1973 (85.0%) participated in the baseline mass blood survey (MBS) and only 52.0% of the total targeted population (1208, 91.9% of total eligible population) completed the TPT. G6PD deficiency was found among 13.5% of total MBS participants and those were excluded from TPT. Of 1315 eligible samples, farmers and gold miners, males, and those aged 15 to 45 years had higher percentages of non-participation in TPT. Qualitative findings showed that most of the non-participation groups were outside the villages during TPT because of time-sensitive agricultural and other occupational or education-related purposes. In addition to mitigating of some inclusion criteria (i.e. including young children or offering weekly PQ treatment to G6PD deficient individuals), strengthening community awareness and increasing engagement should be pursued to increase community participation.
- Published
- 2023
48. Community acceptability, participation, and adherence to mass drug administration with primaquine for Plasmodium vivax elimination in Southern Thailand: a mixed methods approach
- Author
-
Saita, Sayambhu, Roobsoong, Wanlapa, Khammaneechan, Patthanasak, Sukchan, Phnom, Lawpoolsri, Saranath, Sattabongkot, Jetsumon, Cui, Liwang, Okanurak, Kamolnetr, Phuanukoonnon, Suparat, and Parker, Daniel M
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Trials and Supportive Activities ,Rare Diseases ,Malaria ,Vector-Borne Diseases ,Infectious Diseases ,Clinical Research ,Infection ,Good Health and Well Being ,Humans ,Male ,Female ,Primaquine ,Antimalarials ,Plasmodium vivax ,Mass Drug Administration ,Thailand ,Cross-Sectional Studies ,Drug-Related Side Effects and Adverse Reactions ,Malaria ,Vivax ,Acceptability ,Mass drug administration ,Malaria elimination ,Mixed-methods ,Microbiology ,Public Health and Health Services ,Tropical Medicine ,Medical microbiology ,Public health - Abstract
BackgroundMass drug administration (MDA) with primaquine (PQ) is being considered for accelerating Plasmodium vivax elimination in remaining active foci. This study aimed to determine the acceptability of MDA with PQ in malaria endemic villages in a malarious setting in the South of Thailand undergoing MDA with PQ.MethodsA cross-sectional mixed-methods approach was conducted in seven malaria endemic villages where MDA with PQ was implemented. The data were collected from community villagers and health workers using structured questionnaires, in-depth interviews, and focus group discussions. Descriptive statistics and logistic regression models were used for quantitative data analysis. Thematic analysis was applied for qualitative data.ResultsAmong a total of 469 participants from the MDA villages, 293 participants were eligible for MDA with PQ and 79.86% (234) completed 14-days of PQ. The logistic regressions indicated that males (adjusted odds ratio: 2.52 [95% confidence interval: 1.33-4.81]) and those who are farmers (2.57 [1.12-5.90]) were most likely to participate in the MDA. Among 293 participants in the post-MDA study, 74.06% had originally agreed to participate in the MDA with PQ while 25.94% had originally reported not wanting to participate in the MDA. Of those who originally reported being willing to participate in the MDA, 71.23% followed through with participation in the first or second round. Conversely, 93.24% of those who originally reported not being willing to participate in the MDA did in fact participate in the MDA. Factors contributing to higher odds of agreeing to participate and following through with participation included being male (1.98 [1.06-3.69]) and correctly responding that malaria is preventable (2.32 [1.01-5.35]) with some differences by village. Five key themes emerged from the qualitative analyses: concern about side effects from taking PQ; disbelief that malaria could be eliminated in this setting; low overall concern about malaria infections; misunderstandings about malaria; and a general need to tailor public health efforts for this unique context.ConclusionWhile the reported likelihood of participating in MDA was high in this setting, actual follow-through was relatively moderate, partially because of eligibility (roughly 71% of those in the follow-up survey who originally agreed to participate actually followed through with participation). One of the largest concerns among study participants was PQ-related side effects-and these concerns likely heavily influenced participant adherence to the MDA. The results of this study can be used to tailor future MDAs, or other public health interventions, in this and potentially other similar settings.
- Published
- 2023
49. Bioequivalence of a new coated 15 mg primaquine formulation for malaria elimination.
- Author
-
Nguyen Ngoc Pouplin, Julie, Kaendiao, Thoopmanee, Rahimi, Bilal Ahmad, Soni, Mayur, Basopia, Hensi, Shah, Darshana, Patil, Jitendra, Dholakia, Vyom, Suthar, Yash, Tarning, Joel, Mukaka, Mavuto, and Taylor, Walter R.
- Subjects
- *
LIQUID chromatography-mass spectrometry , *PRIMAQUINE , *GLUCOSE-6-phosphate dehydrogenase deficiency , *MALARIA - Abstract
Background: With only one 15 mg primaquine tablet registered by a stringent regulatory authority and marketed, more quality-assured primaquine is needed to meet the demands of malaria elimination. Methods: A classic, two sequence, crossover study, with a 10-day wash out period, of 15 mg of IPCA-produced test primaquine tablets and 15 mg of Sanofi reference primaquine tablets was conducted. Healthy volunteers, aged 18–45 years, without glucose-6-phosphate dehydrogenase deficiency, a baseline haemoglobin ≥ 11 g/dL, creatinine clearance ≥ 70 mL/min/1.73 ms, and body mass index of 18.5–30 kg/m2 were randomized to either test or reference primaquine, administered on an empty stomach with 240 mL of water. Plasma primaquine and carboxyprimaquine concentrations were measured at baseline, then 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.333, 2.667, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0 and 72.0 h by liquid chromatography coupled to tandem mass spectrometry. Primaquine pharmacokinetic profiles were evaluated by non-compartmental analysis and bioequivalence concluded if the 90% confidence intervals (CI) of geometric mean (GM) ratios of test vs. reference formulation for the peak concentrations (Cmax) and area under the drug concentration–time (AUC0–t) were within 80.00 to 125.00%. Results: 47 of 50 volunteers, median age 33 years, completed both dosing rounds and were included in the bioequivalence analysis. For primaquine, GM Cmax values for test and reference formulations were 62.12 vs. 59.63 ng/mL, resulting in a GM ratio (90% CI) of 104.17% (96.92–111.96%); the corresponding GM AUC0–t values were 596.56 vs. 564.09 ngxh/mL, for a GM ratio of 105.76% (99.76–112.08%). Intra-subject coefficient of variation was 20.99% for Cmax and 16.83% for AUC0–t. Median clearances and volumes of distribution were similar between the test and reference products: 24.6 vs. 25.2 L/h, 189.4 vs. 191.0 L, whilst the median half-lives were the same, 5.2 h. Conclusion: IPCA primaquine was bioequivalent to the Sanofi primaquine. This opens the door to prequalification, registration in malaria endemic countries, and programmatic use for malaria elimination. Trial registration The trial registration reference is ISRCTN 54640699 [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study.
- Author
-
Brito, Marcelo, Rufatto, Rosilene, Brito-Sousa, José Diego, Murta, Felipe, Sampaio, Vanderson, Balieiro, Patrícia, Baía-Silva, Djane, Castro, Vanessa, Alves, Brenda, Alencar, Aline, Duparc, Stephan, Grewal Daumerie, Penny, Borghini-Fuhrer, Isabelle, Jambert, Elodie, Peterka, Cássio, Edilson Lima, Francisco, Carvalho Maia, Leonardo, Lucena Cruz, Catherine, Maciele, Bruna, and Vasconcelos, Mariana
- Subjects
- *
PLASMODIUM vivax , *PRIMAQUINE , *HEALTH facilities , *GLUCOSE-6-phosphate dehydrogenase , *SCIENTIFIC observation - Abstract
Prevention of Plasmodium vivax malaria recurrence is essential for malaria elimination in Brazil. We evaluated the real-world effectiveness of an updated treatment algorithm for P vivax radical cure in the Brazilian Amazon. In this non-interventional observational study, we used retrospective data from the implementation of a P vivax treatment algorithm at 43 health facilities in Manaus and Porto Velho, Brazil. The treatment algorithm consisted of chloroquine (25 mg/kg over 3 days) and point-of-care quantitative glucose-6-phosphate dehydrogenase (G6PD) testing followed by single-dose tafenoquine 300 mg (G6PD normal, aged ≥16 years, not pregnant and not breastfeeding), 7-day primaquine 0·5 mg/kg per day (G6PD intermediate or normal, aged ≥6 months, not pregnant, and not breastfeeding or breastfeeding for >1 month), or primaquine 0·75 mg/kg per week for 8 weeks (G6PD deficient, aged ≥6 months, not pregnant, and not breastfeeding or breastfeeding for >1 month). P vivax recurrences were identified from probabilistic linkage of routine patient records from the Brazilian malaria epidemiological surveillance system. Recurrence-free effectiveness at day 90 and day 180 was estimated using Kaplan–Meier analysis and hazard ratios (HRs) by multivariate analysis. This clinical trial is registered with ClinicalTrials.gov , NCT05096702 , and is completed. Records from Sept 9, 2021, to Aug 31, 2022, included 5554 patients with P vivax malaria. In all treated patients of any age and any G6PD status, recurrence-free effectiveness at day 180 was 75·8% (95% CI 74·0–77·6) with tafenoquine, 73·4% (71·9–75·0) with 7-day primaquine, and 82·1% (77·7–86·8) with weekly primaquine. In patients aged at least 16 years who were G6PD normal, recurrence-free effectiveness until day 90 was 88·6% (95% CI 87·2–89·9) in those who were treated with tafenoquine (n=2134) and 83·5% (79·8–87·4) in those treated with 7-day primaquine (n=370); after adjustment for confounding factors, the HR for recurrence following tafenoquine versus 7-day primaquine was 0·65 (95% CI 0·49–0·86; p=0·0031), with similar outcomes between the two treatments at day 180 (log-rank p=0·82). Over 180 days, median time to recurrence in patients aged at least 16 years who were G6PD normal was 92 days (IQR 76–120) in those treated with tafenoquine and 68 days (52–94) in those treated with 7-day primaquine. In this real-world setting, single-dose tafenoquine was more effective at preventing P vivax recurrence in patients aged at least 16 years who were G6PD normal compared with 7-day primaquine at day 90, while overall efficacy at 180 days was similar. The public health benefits of the P vivax radical cure treatment algorithm incorporating G6PD quantitative testing and tafenoquine support its implementation in Brazil and potentially across South America. Brazilian Ministry of Health, Municipal and State Health Secretariats; Fiocruz; Medicines for Malaria Venture; Bill & Melinda Gates Foundation; Newcrest Mining; and the UK Government. For the Portuguese translation of the abstract see Supplementary Materials section. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.